2. GPCR/G Protein Neuronal Signaling Anti-infection
  3. Adrenergic Receptor Influenza Virus Antibiotic
  4. Tulobuterol hydrochloride

Tulobuterol hydrochloride  (Synonyms: C-78)

Cat. No.: HY-W011733 Purity: 99.66%
SDS COA Handling Instructions

Molarity Calculator

Tulobuterol hydrochloride (C-78) is a long-acting β2-adrenoceptor agonist, which reduces the frequency of exacerbations of chronic obstructive pulmonary disease and bronchial asthma. Tulobuterol hydrochloride is also a sympathomimetic agent used as a transdermal patch, increases normal diaphragm muscle strength. Tulobuterol hydrochloride inhibit rhinovirus replication and modulate airway inflammation.

For research use only. We do not sell to patients.

Tulobuterol hydrochloride Chemical Structure

Tulobuterol hydrochloride Chemical Structure

CAS No. : 56776-01-3

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 44 In-stock
Solution
10 mM * 1 mL in DMSO USD 44 In-stock
Solid
250 mg USD 40 In-stock
500 mg USD 70 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Tulobuterol hydrochloride:

Tulobuterol hydrochloride Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Tulobuterol hydrochloride

View All Adrenergic Receptor Isoform Specific Products:

View All Isoforms
α adrenergic receptor β adrenergic receptor

View All Antibiotic Isoform Specific Products:

View All Isoforms
Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Tulobuterol hydrochloride (C-78) is a long-acting β2-adrenoceptor agonist, which reduces the frequency of exacerbations of chronic obstructive pulmonary disease and bronchial asthma. Tulobuterol hydrochloride is also a sympathomimetic agent used as a transdermal patch, increases normal diaphragm muscle strength[1]. Tulobuterol hydrochloride inhibit rhinovirus replication and modulate airway inflammation[2].

IC50 & Target

β2-adrenoceptor[1]
In Vitro

Tulobuterol (0.1 μM; 24 hours or 72 hours; human tracheal epithelial cells) treatment decreases the RV14 RNA levels at 1 day and at 3 days after infection. The concentrations of sICAM-1 in the supernatants of the cells treated with tulobutero are significantly lower than those in the cells treated with vehicle before RV14 infection. Treatment with tulobuterol reduces the number of acidic endosomes with green fluorescence in the cells and the fluorescence intensity of acidic endosomes in the cells. Also reduces the RV14 infection-induced secretion of IL-1β, IL-6, and IL-8. Tulobuterol treatment produces a small but significant reduction in the amount of p50, p65, and c-Rel of NF-κB induced by RV14 infection[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Tulobuterol hydrochloride Related Antibodies

RT-PCR[1]

Cell Line: Human tracheal epithelial cells infected with RV14
Concentration: 0.1 μM
Incubation Time: 24 hours or 72 hours
Result: Decreased the RV14 RNA levels at 1 day and at 3 days after infection. The concentrations of sICAM-1 in the supernatants of the cells were significantly lower. Reduced the number of acidic endosomes with green fluorescence in the cells and the fluorescence intensity of acidic endosomes in the cells. Also reduced the RV14 infection-induced secretion of IL-1β, IL-6, and IL-8. And produced a small but significant reduction in the amount of p50, p65, and c-Rel of NF-κB induced by RV14 infection.
In Vivo

In vivo effect of Tulobuterol is examined the on the contractility of diaphragm muscles prepared from mice (BALBs/c mice; 21.7 ± 0.2 g) treated with Endotoxin. Contractile parameters of force-frequency curves and twitch kinetics using untreated or treated diaphragm muscles at 0 (E0) and 4 (E4) hours after E. coli endotoxin (20 mg/kg) administration are measured. E0 and E4 diaphragm muscles are analyzed at 0, 12, and 24 h after transdermal Tulobuterol treatment. The force-frequency curves of E0 and E4 diaphragm muscles at three time points are not significantly changed each other, indicating that Tulobuterol patch restores the muscle contractility. Thus, diaphragm muscle contractility is maintained during 4 h of endotoxin administration with Tulobuterol patch for over 24 h[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
Molecular Weight

264.19

Formula

C12H19Cl2NO
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

CC(C)(NCC(O)C1=CC=CC=C1Cl)C.Cl
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility
In Vitro: 

H2O : 100 mg/mL (378.52 mM; Need ultrasonic)

DMSO : 50 mg/mL (189.26 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.7852 mL 18.9258 mL 37.8515 mL
5 mM 0.7570 mL 3.7852 mL 7.5703 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (9.46 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (9.46 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 100 mg/mL (378.52 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO / H2O 1 mM 3.7852 mL 18.9258 mL 37.8515 mL 94.6289 mL
5 mM 0.7570 mL 3.7852 mL 7.5703 mL 18.9258 mL
10 mM 0.3785 mL 1.8926 mL 3.7852 mL 9.4629 mL
15 mM 0.2523 mL 1.2617 mL 2.5234 mL 6.3086 mL
20 mM 0.1893 mL 0.9463 mL 1.8926 mL 4.7314 mL
25 mM 0.1514 mL 0.7570 mL 1.5141 mL 3.7852 mL
30 mM 0.1262 mL 0.6309 mL 1.2617 mL 3.1543 mL
40 mM 0.0946 mL 0.4731 mL 0.9463 mL 2.3657 mL
50 mM 0.0757 mL 0.3785 mL 0.7570 mL 1.8926 mL
60 mM 0.0631 mL 0.3154 mL 0.6309 mL 1.5771 mL
80 mM 0.0473 mL 0.2366 mL 0.4731 mL 1.1829 mL
100 mM 0.0379 mL 0.1893 mL 0.3785 mL 0.9463 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Tulobuterol hydrochloride Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tulobuterol56776-01-3C-78C78C 78Adrenergic ReceptorInfluenza VirusAntibioticBeta ReceptorInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Tulobuterol hydrochloride
Cat. No.:
HY-W011733
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (392 KB) Français - FR (392 KB) Deutsch - DE (392 KB) Norwegian - NO (392 KB) Español - ES (392 KB) Swedish - SV (392 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.